11:40 AM EST - Avivagen Inc. : provided a summary of the final results of the first exploratory evaluation of Avivagen's proprietary OxC-beta in aquaculture under production conditions; a tilapia trial run by Nam Sai Farms of Thailand. Avivagen Inc.
shares V.VIV are trading down $0.005 at $0.08.
